To include your compound in the COVID-19 Resource Center, submit it here.

Royalty’s $1.7B IPO latest sign of a biopharma market on a roll

Four companies set terms for NASDAQ IPOs: Repare, Forma, Progenity and Genetron

Royalty Pharma priced the year’s second-largest biopharma IPO to date and then saw its shares rise nearly 60%, the latest sign of a robust appetite for fresh paper from life sciences companies. The investment firm’s offering also earned it the largest

Read the full 411 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE